Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 172, pseudogene (RN7SL172P) is classified as a non-coding RNA pseudogene. It is a member of a large family of human genomic sequences related to the functional 7SL RNA, a component of the signal recognition particle (SRP), but unlike the authentic gene, this locus does not produce a functional RNA or protein[1][6][7]. Pseudogenes like RN7SL172P arise through duplication or retrotransposition events followed by loss of function, often resulting in truncated, nonfunctional RNA sequences[6][7]. As a pseudogene, RN7SL172P does not contribute to canonical cellular signaling, enzymatic activity, or therapeutic targeting and has no known role in disease, drug interaction, or biomarker status[1][6][7]. There is no evidence it functions as a therapeutic target, nor does it have established involvement in pharmacology, disease mechanisms, or safety profiles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 172, pseudogene (RN7SL172P).